Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop in stock value, equating to a 32.4% decline [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the concealment of critical operational issues, emphasizing the impact of management's narrative on the stock's performance [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [6].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical's new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting the company's assurances of a successful launch [2] - Allegations include that Inspire Medical failed to complete essential tasks for the product launch, such as training for treatment center customers, setting up IT systems, and ensuring Medicare reimbursement was in place [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with investors encouraged to contact BFA Law by January 5, 2026, to lead the case [1][3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, but failed to prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing allegations of misleading investors regarding the launch of its new product, Inspire V, which reportedly failed due to poor demand and inadequate preparations [3][4]. Group 1: Allegations and Issues - The class period for the allegations is from August 6, 2024, to August 4, 2025 [3]. - The complaint states that the launch of Inspire V was a disaster, with significant surplus inventory and reluctance from providers to transition to the new treatment [3]. - Defendants allegedly made false statements about the successful launch, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [3][4]. Group 2: Shareholder Actions - Shareholders who purchased INSP shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of January 5, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that led to artificial inflation of the company's stock [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its new device, Inspire V, leading to significant financial losses for investors [1][2]. Summary by Relevant Sections Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for full commercial rollout, which concealed critical operational failures [2][4]. - The lawsuit highlights that the necessary software updates for Medicare claims processing did not take effect until July 1, 2025, delaying the rollout and revenue generation [3]. - There was a significant surplus of the older Inspire IV device, which impacted demand for the new Inspire V product, leading to a drastic cut in 2025 EPS guidance by over 80% [3]. Financial Impact - The stock price of Inspire Medical dropped by $42.04 per share, representing a 32.4% decline in value following the revelation of these operational issues [3]. - The lawsuit claims that many treatment centers had not completed the essential training and onboarding required to implant the new device, further complicating the launch [3]. Legal Actions and Investor Rights - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, including the Medicare claims software failure and the inventory glut of the prior device [4].

Core Viewpoint - Inspire Medical Systems, Inc. is facing allegations of misleading investors regarding the launch of its new product, Inspire V, which reportedly failed due to poor demand and inadequate preparations [1][2]. Allegations - The complaint states that the company made false statements and concealed the fact that the launch of Inspire V was unsuccessful, with providers having excess inventory and hesitating to adopt the new treatment [1]. - Key failures cited include incomplete training and onboarding for treatment center customers, lack of established IT systems, and unpreparedness for Medicare reimbursement at launch [1]. Class Action Details - Shareholders who purchased shares during the class period from August 6, 2024, to August 4, 2025, are encouraged to register for the class action, with a deadline of January 5, 2026, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to hold companies accountable for misleading statements that lead to stock inflation and investor losses [3].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 to $87.91 per share [8].

Core Insights - The Mairs & Power Small Cap Fund reported a return of 2.06% in the first nine months of 2025, underperforming against benchmarks such as the Russell 2000 Total Returns Index, which increased by 10.39% [1] - The market remains concentrated in 2025, with a few dominant mega-cap stocks related to artificial intelligence driving most favorable outcomes [1] Fund Performance - The fund's performance lagged behind the S&P Small Cap 600 TR, which rose by 4.24%, and the Morningstar U.S. Fund Small Blend, which returned 6.15% [1] Company Focus: Inspire Medical Systems, Inc. - Inspire Medical Systems, Inc. (NYSE:INSP) is highlighted as a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea [2] - The stock of Inspire Medical Systems experienced a one-month return of 61.41%, but it lost 26.28% over the last 52 weeks, closing at $140.07 per share with a market capitalization of $4.142 billion on December 10, 2025 [2] Performance Challenges - Inspire Medical Systems was noted as a detractor from relative performance due to challenges related to increased GLP-1 usage, new product rollout issues, and delays with billing software and reimbursement codes [3] Hedge Fund Interest - Inspire Medical Systems is not among the 30 most popular stocks among hedge funds, with 48 hedge fund portfolios holding the stock at the end of Q3 2025, up from 34 in the previous quarter [4] Financial Performance - In Q3 2025, Inspire Medical Systems reported revenue of $224.5 million, marking a 10% increase from Q3 2024 [4] - Despite the potential of Inspire Medical Systems as an investment, certain AI stocks are considered to offer greater upside potential and less downside risk [4]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged violations of securities laws, specifically related to misleading statements about the launch of its Inspire V therapy system [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, with a deadline for lead plaintiff appointments set for January 5, 2026 [2]. - The complaint alleges that Inspire Medical Systems made false and misleading statements, leading investors to believe in strong market demand for the Inspire V therapy system, which ultimately faced weak demand upon launch [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its next-generation device, the Inspire V, leading to significant financial losses for investors [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its operational readiness for the Inspire V launch, stating it was ready for a full commercial rollout, while concealing critical operational failures [3][4]. - Key undisclosed operational issues included delays in Medicare claims processing software updates, which only took effect on July 1, 2025, causing revenue bottlenecks [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, necessitating an inventory "burn down" [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, further hindering the launch [4]. Group 2: Financial Consequences - The alleged operational failures led Inspire Medical to cut its 2025 earnings per share (EPS) guidance by over 80%, resulting in a significant stock price drop of $42.04 per share, equating to a 32.4% decline in value [4][5]. - The lawsuit highlights that the stock collapse was attributed to management prioritizing a narrative of seamless transition over the actual operational challenges faced [5]. Group 3: Legal and Investigative Actions - Hagens Berman, the law firm leading the investigation, is encouraging investors who suffered losses during the class period from August 6, 2024, to August 4, 2025, to contact them before the January 5, 2026, lead plaintiff deadline [2][3]. - The firm is particularly focused on the concealment of the Medicare claims software failure and the inventory issues related to the Inspire IV device [5].